News Column

Research Conducted by H. Prucha and Co-Authors Has Provided New Information about Intracellular Signaling Peptides and Proteins

June 18, 2014

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Intracellular Signaling Peptides and Proteins are discussed in a new report. According to news reporting out of Munich, Germany, by NewsRx editors, research stated, "Pimecrolimus , a calcineurin inhibitor, is a non-steroidal treatment option in patients aged ? 2 years with mild-to-moderate atopic eczema (AE). It was approved as a viable therapeutic option by the FDA in 2001 and in the European Union a year later in 2002."

Our news journalists obtained a quote from the research, "Calcineurin inhibitors inhibit the synthesis of inflammatory cytokines released from T cells and mast cells. In contrast to corticosteroids, calcineurin inhibitors act specifically on proinflammatory cells. Pimecrolimus shows comparative efficacy to mild topical corticosteroids and a special antipruritic effect. Furthermore, examinations of the systemic absorption of pimecrolimus implicated no systemic immunosuppression. In 2006, the FDA set a black box warning in the packaging materials of pimecrolimus alluding to the risk of skin malignancy or lymphomas due to theoretical consideration. The authors provide a review of pimecrolimus as a treatment for AE. Specifically, the authors present the pharmacokinetic and pharmacodynamic information on pimecrolimus and also review its efficacy. The authors also discuss pimecrolimus' safety and tolerability profile. Pimecrolimus represents a valuable part of active and proactive therapy in AE. That being said, the long-term safety of topical calcineurin inhibitors remains to be investigated. Given the results from experimental photocarcinogenicity studies, effective sun protection should be employed during the therapy, although an increased risk for skin malignancies and lymphomas was not found in recent studies."

According to the news editors, the research concluded: "Pimecrolimus should be considered as an alternative therapeutic approach in AE treatment management going along with a corticoid-sparing effect."

For more information on this research see: Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. Expert Opinion On Drug Metabolism & Toxicology, 2013;9(11):1507-16 (see also Intracellular Signaling Peptides and Proteins).

Our news journalists report that additional information may be obtained by contacting H. Prucha, TU Munich, Dermatology , Biedersteiner Straße 29, Munich 80802 , Germany. Additional authors for this research include C. Schnopp, C. Akdis, R. Lauener, A. Wollenberg, J. Ring and C. Traidl-Hoffmann.

Keywords for this news article include: Munich, Europe, Germany, Therapy, Calcineurin, Intracellular Signaling Peptides and Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters